Drug Profile


Alternative Names: ARH 061746; AZD 3355

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; University Hospital of South Manchester NHS Foundation Trust
  • Class Phosphinic acids; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cough; Gastro-oesophageal reflux

Most Recent Events

  • 01 Sep 2017 AstraZeneca completes a phase II trial in Cough in United Kingdom (PO) (EudraCT2014-005074-11)
  • 29 Oct 2010 Discontinued - Phase-I for Gastro-oesophageal reflux in Sweden (PO)
  • 29 Oct 2010 Discontinued - Phase-II for Gastro-oesophageal reflux in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top